Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Drisapersen in DMD
NCT01803412Phase 3Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- May 2013
- Primary completion
- Jun 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 3 trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Started May 2013; status: terminated.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01803412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803412.